Early rise in exhaled nitric oxide and mast cell activation in repeated low-dose allergen challenge

European Respiratory Journal

Volumn 27, Issue 6, 2006, Pages 1152-1159

  Ihre, E ^a   Gyllfors, P ^a   Gustafsson, L E ^b   Kumlin, M ^b   Dahlén, Barbro ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Adenosine 5 monophosphate; Airway hyperresponsiveness; Allergic asthma; Exhaled nitric oxide; Leukotrienes; Prostaglandins

Indexed keywords

9ALPHA11BETA PROSTAGLANDIN F2; ADENOSINE; ALLERGEN; DILUENT; HISTAMINE; LEUKOTRIENE E4; NITRIC OXIDE; PROSTAGLANDIN F2; ADENOSINE PHOSPHATE; DIAGNOSTIC AGENT; LEUKOTRIENE; PROSTAGLANDIN;

ADULT; ALLERGIC ASTHMA; ARTICLE; BRONCHUS HYPERREACTIVITY; CELL ACTIVATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION TEST; MALE; MAST CELL; PNEUMONIA; PRIORITY JOURNAL; PROVOCATION TEST; SYMPTOM; URINALYSIS; ANIMAL; ASTHMA; BREATH ANALYSIS; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; INTRACUTANEOUS TEST; PHYSIOLOGY; POLLEN; REFERENCE VALUE; RESPIRATORY TRACT ALLERGY;

ADENOSINE MONOPHOSPHATE; ADMINISTRATION, INHALATION; ADULT; ALLERGENS; ANIMALS; ASTHMA; BREATH TESTS; CROSS-OVER STUDIES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INTRADERMAL TESTS; LEUKOTRIENES; MALE; MAST CELLS; NITRIC OXIDE; POLLEN; PROSTAGLANDINS; REFERENCE VALUES; RESPIRATORY HYPERSENSITIVITY;

EID: 33750713647     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.06.00142905     Document Type: Article

References (30)

1. Ihre E, Zetterström O. Increase in non-specific bronchial responsiveness after repeated inhalation of low doses of allergen. Clin Exp Allergy 1993; 23: 298-305.
2. Sulakvelidze I, Inman MD, Rerecich T, O'Byrne PM. Increases in airway eosinophils and interleukin-5 with minimal bronchoconstriction during repeated low-dose allergen challenge in atopic asthmatics. Eur Respir J 1998; 11: 821-827.
3. Arshad SH, Hamilton RG, Adkinson NF Jr. Repeated aerosol exposure to small doses of allergen: a model for chronic allergic asthma. Am J Respir Crit Care Med 1998; 157: 1900-1906.
4. Palmqvist M, Pettersson K, Sjöstrand M, Anderson B, Löwhagen O, Lötvall JO. Mild experimental exacerbations of asthma induced by individualised low-dose repeated allergen exposure: a doubl-blind evaluation. Respir Med 1998; 92: 1223-1230.
5. De Blay F, Krieger P, Spirlet F, et al. Repeated inhalation of low doses of cat allergen that do not cause clinical symptoms increases bronchial hyperresponsiveness and eosinophil cationic protein levels. Int Arch Allergy Immunol 1999; 120: 158-165.
6. Palmqvist M, Cui Z-H, Sjöstrand M, Lindén A, Lötvall JO. Reduced late asthmatic response by repeated low-dose allergen exposure. Eur Respir J 2001; 17: 872-880.
7. Gauvreau GM, Sulakvelidze I, Watson RM, Inman MD, Rerecich TJ, O'Byrne PM. Effects of once daily dosing with inhaled budesonide on airway hyperresponsiveness and airway inflammation following repeated low-dose allergen challenge in atopic asthmatics. Clin Exp Allergy 2000; 30: 1235-1243.
8. De Kluijver J, Evertse CE, Schrumpf JA, et al. Asymptomatic worsening of airway inflammation during low-dose allergen exposure in asthma. Am J Respir Crit Care Med 2002; 166: 294-300.
9. Roquet A, Lagging E, Ihre E, et al. No signs of activity markers in peripheral blood despite increased bronchial reactivity after repeated low-dose allergen exposure. APMIS 1998; 106: 293-299.
10. Lensmar C, Prieto J, Dahlén B, Eklund A, Grunewald J, Roquet A. Airway inflammation and altered macrophage phenotype pattern after repeated low-dose allergen exposure of atopic asthmatic subjects. Clin Exp Allergy 1999; 29: 1632-1640.
11. 2 in vivo. Thorax 2004; 59: 453-455.
12. O'Sullivan S, Roquet A, Dahlén B, Kumlin M, Dahlén SE. Urinary excretion of inflammatory mediators during early and late phase allergen-induced airway obstruction. Clin Exp Allergy 1998; 28: 1332-1339.
13. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000; 356: 2144-2148.
14. Björck T, Gustafsson LE, Dahlén S-E. Isolated bronchi of asthmatics are hyperresponsive to adenosine which apparently acts indirectly by liberation of leukotrienes and histamine. Am Rev Respir Dis 1992; 145: 1087-1091.
15. Peachell PT, Columbo M, Kagey-Sobotka A, Lichtenstein LM, Marone G. Adenosine potentiate mediator release from human lung mast cells. Am Rev Respir Dis 1988; 138: 1143-1151.
16. Rorke S, Jennison S, Jeffs JA, Sampson AP, Arshad H, Holgate ST. Role of cysteinyl leukotrienes in adenosine 5′-monophosphate induced bronchoconstriction in asthma. Thorax 2002; 57: 323-327.
17. Van Den Berge M, Meijer RJ, Kerstjens HA, et al. PC20 Adenosine 5′-monophosphate is more closely associated with airway inflammation in asthma than PC20 methacholine. Am J Respir Crit Care Med 2001; 163: 1546-1550.
18. Currie GP, Jacksaom CM, Lee DK, Lipworth BJ. Allergen sensitization and bronchial hyperresponsiveness to adenosine monophosphate in asthmatic patients. Clin Exp Allergy 2003; 33: 1005-1008.
19. Roquet A, Dahlén B, Kumlin M, et al. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Respir Crit Care Med 1997; 155: 1856-1863.
20. Joos GF, O'Connor on behalf of the ERS Task Force, Indirect challenges. Eur Respir J 2003; 21: 1050-1068.
21. American Thoracic Society (ATS)/European Respiratory (ERS) recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. This joint statement of the ATS and the ERS was adopted by the ATS Board of Directors, December 2004, and by the ERS Executive Committee, June 2004. Am J Respir Crit Care 2005; 171: 912-930.
22. Kumlin M, Stensvad F, Larsson L, Dahlén B, Dahlén SE. Validation and application of a new simple strategy for measurements of leukotriene E4 in human urine. Clin Exp Allergy 1995; 25: 467-479.
23. O'Sullivan S, Dahlén B, Dahlén SE, Kumlin M. Increased urinary excretion of the prostaglandin D2 metabolite, 9 alpha, 11 beta prostaglandin F2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. J Allergy Clin Immunol 1996; 98: 421-432.
24. Kharitonov SA, Gonio F, Kelly C, Meah S, Barnes PJ. Reproducibility of exhaled nitric oxide measurements in healthy and asthmatic adults and children. Eur Respir J 2003; 21: 433-438.
25. De Kluijver J, Evertse CE, Sont JK, et al. Are rhinovirus-induced airway responses in asthma aggravated by chronic allergen exposure? Am J Respir Crit Car Med 2003; 168: 1174-1180.
26. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. New Engl J Med 2005; 352:2163-2173.
27. Tattersfield AE, Postma DS, Barnes PJ, et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med 1999; 160: 594-599.
28. Kumlin M. Measurement of leukotrienes in humans. Am J Respir Crit Care Med 2000; 161: S102-S106.
29. Larsson AK, Back M, Hjoberg J, Dahlén S-E. Inhibition of nitric-oxide synthase enhances antigen-induced contractions and increases release of cysteinyl-leukotrienes in guinea pig lung parenchyma: nitric oxide as a protective factor. J Pharmacol Exp Ther 2005; 315: 458-465.
30. Leckie MJ. Chronic allergen challenge as an experimental model: necessary, significant or useful? Clin Exp Allergy 2000; 30: 1191-1193.